Ajay Major, MD, MBA
@majorajay.bsky.social did:plc:plgt5bqnko7dwhzi2436ipuf
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
No Bluesky desde
- Seguidores
- 588
- Seguindo
- 252
- Posts
- 539
- Dias nos rankings
- 0
Resumo
Ajay Major, MD, MBA (@majorajay.bsky.social) é um usuário do Bluesky desde 11 novembro 2024. Tem 588 seguidores, segue 252 contas e publicou 539 posts.
Aparições nos rankings
Os melhores dias em que posts desta conta entraram na lista diária do Debya.
Esta conta ainda não apareceu em um ranking diário.
Posts curtidos recentemente
Curtidas públicas da rede Bluesky.
Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...
Ver postSelf-promotion. news.cuanschutz.edu/cancer-cente...
Ver postJamie Studts, PhD, leads with earnestness, collaboration, and deep respect for community voice — encouraging researchers to pursue what they’re passionate about while grounding science in real-world impact. Full interview: youtu.be/RihtmBmGlIk
Ver postCAR T-cell therapy has revolutionized treatment of stubborn cancers. Now, a groundbreaking study from @cucancercenter.bsky.social researchers addresses “a huge unanswered gap” in how CAR T-cell therapy impacts patients over two years. @cuanschutz.bsky.social @majorajay.bsky.social #cucityofhealth
Ver postIn a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: https://bit.ly/3UzIYxF
Ver post
Contas que bloqueia
No Bluesky, bloqueios são registros públicos.